SEC Form 4 · accession 0000899243-16-026739
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter K. Watler
Officer — Chief Technical Officer
Period of report
Aug 8, 2016
Accepted (ET)
Aug 10, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Aug 8, 2016 | M | 40,000 | $2.0838 | A | 40,000 | D | |
| Common Stock, $0.0001 par valueF2 | Aug 8, 2016 | S | 40,000 | $30.0004 | D | 0 | D | |
| Common Stock, $0.0001 par value | Aug 8, 2016 | M | 15,621 | $2.5005 | A | 15,621 | I | By Wife |
| Common Stock, $0.0001 par valueF4 | Aug 8, 2016 | S | 15,621 | $30.0012 | D | 0 | I | By Wife |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $2.0838 | Aug 8, 2016 | M | 40,000 | D | — | Dec 13, 2022 | Common Stock | 40,000 | 48,503 | D |
| Stock Option (right to buy)F6 | $2.5005 | Aug 8, 2016 | M | 15,621 | D | — | Jun 29, 2024 | Common Stock | 15,621 | 14,373 | I |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The transaction was executed in multiple trades in prices ranging from $30.00 to $30.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F3The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's wife.
- F4The transaction was executed in multiple trades in prices ranging from $30.00 to $30.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F5All shares underlying this option are vested and exercisable as of the date hereof.
- F6A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 29, 2014, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.